Adjuvants in biopharmaceuticals have been used mainly for human vaccine development to reinforce immunogenicity of vaccines until now. However, it has expanded its applications to other therapeutics such as oncology and treatment for autoimmune diseases, as its specific mechanism of immunity enhancement has been recently identified and immunotherapy to cure the diseases by regulating the human immune system in the limelight. EuBiologics is developing Human Papilloma Virus (HPV) vaccines and EUPOP Life Sciences, a joint venture based in USA, is under development of the vaccine against COVID-19, Respiratory Syncytial Virus (RSV), Herpes Zoster Virus (HZV) and Alzheimer’s Disease with EcML.
|Product Name||Monophosphoryl lipid A from recombinant E.coli|
|Product Purpose||For research only|